-
Kenya's economy faces climate change risks: World Bank
-
Stocks rise ahead of US-China summit
-
US wholesale prices jump 6.0% year-on-year in April, highest since 2022
-
Italy cheers UK's Catherine on first foreign visit since cancer diagnosis
-
Eurovision stage inspired by Viennese opera
-
Stocks waver, oil steady ahead of US-China summit as Iran talks stall
-
War in Middle East: latest developments
-
After the hobbits, director Peter Jackson tackles 'Tintin'
-
Real Madrid win legal battle over Bernabeu concert noise
-
EU won't ban LGBTQ 'conversion therapy' but will push states to act
-
Heckler ejected from Eurovision after Israel song disruption
-
Trump arrives in China for superpower summit with Xi
-
UK's Catherine on first official foreign trip since cancer diagnosis
-
British scientists among winners of top Spanish award
-
Chinese tech giant Alibaba posts profit drop amid AI drive
-
King Charles lays out Starmer's agenda as PM fights for survival
-
Stocks rise ahead of US-China summit as Iran talks stall
-
SoftBank profit quadruples to $32 bn on AI investments
-
China tech giant Tencent sees Q1 profit jump after AI bets
-
Nissan expects return to profit after huge loss
-
Asian stocks mixed on US-Iran impasse, AI setbacks
-
UK's Catherine on first official foreign trip since cancer revelation
-
'Short of blue-collar workers': Ukraine's battle for labour
-
AI rivalry overshadows push for guardrails at Xi-Trump talks: experts
-
Asian stocks fall on US-Iran impasse, AI setbacks
-
'I applied to be pope': Losing grip on reality while using ChatGPT
-
EU to ease train travel with one journey, one ticket rules
-
Paramount defends Warner bid amid California probe
-
Agnete Kirk Kristiansen Appointed Chair of the LEGO Foundation
-
Favourites Finland, Israel through at Eurovision semis
-
Musk 'wanted 90%' of OpenAI, Altman tells tech titan trial
-
Oil prices advance, stocks mostly fall on US-Iran deadlock
-
Musk 'wanted 90%' of OpenAI, Altman says in high-stakes trial
-
US appeals court halts order declaring Trump's global 10% tariff illegal
-
Showtime as boycotted Eurovision kicks off
-
Kevin Warsh returns to Federal Reserve with 'regime change' agenda
-
Fabled Argentine city Ushuaia tries to shrug off virus suspicions
-
US Senate confirms Trump-nominee Warsh to Federal Reserve board
-
Wine consumption slides in 2025
-
Trump due in China for superpower summit with Xi
-
Sam Altman to testify at California tech titan trial
-
US consumer inflation hits three-year high fuelled by Iran war
-
Cannes honours Jackson, Middle Earth wizard who 'transformed' cinema
-
Oil prices jump, stocks retreat on US-Iran deadlock
-
South Korea official floats AI profit social tax as tech giants boom
-
Vodafone sees signs of recovery amid turnaround plan
-
Bayer profit up but glyphosate sales struggle
-
New London museum woos younger visitors
-
Japan crisp packs to go colourless due to Iran war crunch
-
'Genuine urgency': China's underlying concerns at the Xi-Trump talks
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
X.Cheung--CPN